The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge in MPN, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
4 Aug 2026
Symposium | Advanced systemic mastocytosis: Therapeutic landscape: Evidence-based strategies across the disease spectrum
At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes. During the symposium, Alessandro Vannucchi, University of Florence, Florence, IT, discussed evidence-based treatment strategies across the disease spectrum of advanced systemic mastocytosis (AdvSM).
In this presentation, Vannucchi reviews the evolving therapeutic landscape in AdvSM, highlighting considerations that influence treatment selection across disease subtypes. Vannucchi discusses historical and contemporary treatment approaches, clinical evidence for KIT-targeted therapies, evolving goals for treatment, and emerging therapeutic strategies that may further inform future clinical management.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
2 Aug 2026
Symposium | Looking ahead: Future directions and unanswered questions in AdvSM
At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes.
The symposium closed with a panel Q&A session with live audience participation. The panelists, Deepti H Radia, Andreas Reiter, Johannes Lübke, and Alessandro Vannucchi, discussed key challenges in advanced systemic mastocytosis (AdvSM), including underdiagnosis and complexities in the management of SM with an associated hematologic neoplasm (AHN), and mast cell leukemia (MCL). They also discussed emerging combination therapies and highlighted allogeneic hematopoietic stem cell transplantation (allo-HSCT) as the only potentially curative option in AdvSM, emphasizing the importance of optimal disease control prior to transplantation.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
597,144
Score snapshot 15 Sept 2025
Apple Podcasts (US)
3.0 / 5
2 ratings
Podcast Authority Score: 37 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
27
Social presence
0
YouTube
86
Engagement
30
Contact MPN Hub
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of MPN Hub?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
